Johnson & Johnson

2Q Revenues: $23.3 billion (+27%)

2Q Earnings: $6.3 billion (+73%)

Comments: Pharmaceutical sales were up 17% to $12.6 billion in the quarter, driven by STELARA for the treatment of

immune-mediated inflammatory diseases, up 34% to $2.3 billion; DARZALEX for the treatment of multiple myeloma, up 59% to $1.4 billion; TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, up 40% to $479 million; ERLEADA (apalutamide), for the treatment of prostate cancer, up 78% to $302 million; IMBRUVICA (ibrutinib) for treating certain B-cell malignancies, up 18% to $1.1 billion; and INVEGA

SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia, up 18% to $1.0 billion. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for a number of immune-mediated inflammatory diseases, down 5% to $888 million. R&D expenses were up 25% to $3.4 billion. RYBREVANT (amivantamab-vmjw) received U.S. FDA approval as the first targeted treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) received U.S. FDA approval for combination with Pomalidomide and Dexamethasone for patients with Multiple Myeloma after first or subsequent relapse.